SLC6A16

Across TCGA pan-cancer cohorts, SLC6A16 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of SLC6A16’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where SLC6A16 RNA is repressed in tumor relative to normal tissue. In most cancer types SLC6A16 is over-expressed in tumor, although a few such as THCA and KIRC show the opposite, repressed pattern.

THCA, KIRC, and BLCA are the cancer types where SLC6A16 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC6A16 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	III,IV	−1.275	<.001	11	view →
KIRC	Male	II,III,IV	−1.049	<.001	11	view →
BLCA	Male	IV	−1.590	<.001	9	view →
LUAD	Female	II,III,IV	−0.830	<.001	9	view →
COAD	Male	All	−0.421	<.001	8	view →
LUSC	All	III,IV	−1.259	<.001	7	view →
BRCA	All	III,IV	−0.711	<.001	6	view →
READ	All	All	−0.526	.006	2	view →
PRAD	All	All	−0.419	<.001	2	view →
LIHC	All	II,III,IV	−0.337	.021	2	view →
ESCA	All	All	−0.665	.036	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

SLC6A16–THCA

Open the THCA breakdown →